Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure

American Heart Journal

Volumn 139, Issue 6, 2000, Pages 1000-1008

  Vaitkus, Paul T ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; GEMFIBROZIL; HEPARIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MYOGLOBIN; NADOLOL; RECOMBINANT ERYTHROPOIETIN; SIMVASTATIN; TROPONIN T;

ANEMIA; ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE; MYOSITIS; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; UREMIA;

EID: 0034120220     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.105300     Document Type: Article

References (89)

1. USRDS 1995 annual data report, VI: causes of death. Am J Kidney Dis 1995;26:S85-94.
2. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805.
3. Lindner A, Charra B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
4. Nichols AJ, Edward N, Catto GRD, et al. Accelerated atherosclerosis in long-term dialysis and renal-transplant patients: fact or fiction? Lancet 1980;1:276-8.
5. Burke JF, Francos GC, Moore LL, et al. Accelerated atherosclerosis in chronic-dialysis patients: another look. Nephron 1978;21:181-5.
6. Singh N, Langer A, Freeman MR, et al. Myocardial alterations during hemodialysis: insights from new noninvasive technology. Am J Nephrol 1994;14:173-81.
7. Morales MA, Gremigni C, Dattolo P, et al. Signal-averaged ECG abnormalities in haemodialysis patients: role of dialysis. Nephrol Dial Transplant 1998;13:668-73.
8. Shapira OM, Bar-Khayim Y. ECG changes and cardiac arrhythmias in chronic renal failure patients on hemodialysis. J Electrocardiol 1992;25:273-9.
9. Sforzini S, Latini R, Mingardi G, et al. Ventricular arrhythmias and 4-year mortality in haemodialysis patients. Lancet 1992;339:212-3.
10. Cheigh JS, Serur D, Paguirigan M, et al. How well is hypertension controlled in CAPD patients? Adv Perit Dial 1994;10:55-8.
11. Anderson CF. Hyperlipoproteinemia in adults with renal disease. Mayo Clin Proc 1993;68:358-62.
12. Kaysen GA. Hyperlipidemia of chronic renal failure. Blood Purif 1994;12:60-7.
13. Appel G. Lipid abnormalities in renal disease. Kidney Int 1991;39:169-83.
14. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1996;21:573-92.
15. Cheung AK, Wu LL, Kablitz C, et al. Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 1993;22:271-6.
16. Kronenberg F, Konig P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995;6:110-20.
17. Cressman MD, Heyka RJ, Paganini EP, et al. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992;86:475-82.
18. Ramos JM, Heaton A, McGurk JG, et al. Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis. Nephron 1983;35:20-3.
19. Avram MM, Goldwasser P, Burrell DE, et al. The uremic dyslipidemia: a cross-sectional and longitudinal study. Am J Kidney Dis 1992;20:324-35.
20. Knauf H, Kolle EU, Mutschler E. Gemfibrozil absorption and elimination in kidney and liver disease. Klin Wochenschr 1990;68:692-8.
21. Chow LTC, Chow W. Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis. Med J Aust 1993;158:48-9.
22. Thompson CH, Irish A, Kemp GJ, et al. Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure. Clin Nephrol 1996;45:386-9.
23. Wanner C, Horl WH, Luley CH, et al. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 1991;39:754-60.
24. Dinitriadis A, Antoniou S, Hatzissavvas N, et al. The effect of simvastatin on dyslipemia in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993;13:S434-6.
25. Harris DCH, Simone LA, Mitchell P, et al. Management of non-nephrotic hyperlipidaemia of chronic renal failure with simvastatin. Med J Aust 1991;155:573.
26. Wanner C, Lubrich-Birkner I, Summ O, et al. Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients. Nephron 1992;62:40-6.
27. Zidek W. Homocysteine: a new arteriosclerotic risk factor in end-stage renal failure. Nephron 1997;75:249-50.
28. Chauveau P, Chadefaux B, Coude M, et al. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 1996;22:106-9.
29. Kremastinos D, Paraskevaidis I, Voudiklari S, et al. Painless myocardial ischemia in chronic hemodialysed patients: a real event? Nephron 1992;60:164-70.
30. Boudreau RJ, Strony JT, duCret RP, et al. Perfusion thallium imaging of type I diabetes patients with end stage renal disease: comparison of oral and intravenous dipyridamole administration. Radiology 1990;175:103-5.
31. Marwick TH, Steinmuller DR, Underwood DA, et al. Ineffectiveness of dipyridamole SPECT thallium imaging as a screening technique for coronary artery disease in patients with end-stage renal failure. Transplantation 1990;49:100-3.
32. Welsh RC, Cockfield S, Halloran P, et al. Noninvasive cardiac assessment of diabetic nephropathy renal transplant candidates. J Am Coll Cardiol 1999;33:335A.
33. Dahan M, Viron BM, Faraggi M, et al. Diagnostic accuracy and prognostic value of combined dipyridamole-exercise thallium imaging in hemodialysis patients. Kidney Int 1998;54:255-62.
34. Reis G, Marcovitz PA, Leichtman AB, et al. Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease. Am J Cardiol 1995;75:707-10.
35. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients. Am J Kidney Dis 1996;27:394-401.
36. Holley JL, Fenton RA, Arthur RS. Thallium stress testing does not predict cardiovascular risk in diabetic patients with end-stage renal disease undergoing cadaveric renal transplantation. Am J Med 1991;90:563-70.
37. Brown KA, Rimmer J, Haisch C. Noninvasive cardiac risk stratification of diabetic and nondiabetic uremic renal allograft candidates using dipyridamole-Thallium-201 imaging and radionuclide ventriculography. Am J Cardiol 1989;64:1017-21.
38. Camp AD, Garvin PJ, Hoff J, et al. Prognostic value of intravenous dipyridamole thallium imaging in patients with diabetes mellitus considered for renal transplantation. Am J Cardiol 1990;65:1459-63.
39. Kasiske BL, Ramos EL, Gaston RS, et al. The evaluation of renal transplant candidates: clinical practice guidelines. J Am Soc Nephrol 1995;6:1-34.
40. Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography: executive summary and recommendations. Circulation 1999;99:2345-57.
41. Brown JH, Vites NP, Testa HJ, et al. Value of thallium myocardial imaging in the prediction of future cardiovascular events in patients with end-stage renal failure. Nephrol Dial Transplant 1993;8:433-7.
42. Le A, Wilson R, Douek K, et al. Prospective risk stratification in renal transplant candidates for cardiac death. Am J Kidney Dis 1994;24:65-71.
43. Bennett WM, Aronoff GR, Golper TA, et al. Drug prescribing in renal failure: dosing guidelines for adults. 3rd edition. Philadelphia (Pa): American College of Physicians; 1994.
44. Kooistra MP, van Es A, Marx JJ, et al. Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrol Dial Transplant 1994;9:1115-20.
45. Tun A, Khan IA, Win MT, et al. Specificity of cardiac troponin I and creatine kinase-MB isoenzyme in asymptomatic long-term hemodialysis patients and effects of hemodialysis on these cardiac markers. Cardiology 1999;90:280-5.
46. Herzog CA, Ma J, Collins AJ. Outcome of dialysis patients receiving thrombolytic therapy for acute myocardial infarction (AMI) in the United States. Circulation 1997;96:1-202.
47. Physicians' desk reference. 53rd edition. Montvale (NJ): Medical economics Co; 1999.
48. Ifudu O, Miles AM, Friedman EA. Hemodialysis immediately after acute myocardial infarction. Nephron 1996;74:104-9.
49. Kong TQ, Dacanay S, Hsieh AA. Features of acute myocardial infarction in patients on chronic hemodialysis. Circulation 1994;88:1-49.
50. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase II multicenter clinical trial. Ann Intern Med 1989;111:992-1000.
51. Low-Friedrich I, Grutzmacher P, Marz W, et al. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 1991;11:54-60.
52. Hase H, Imamura Y, Nakamura Y, et al. Effects of rHuEPO therapy on exercise capacity in hemodialysis patients with coronary artery disease. Jpn Circ J 1993;57:131-7.
53. Wizemann V, Kaufmann J, Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992;62:161-5.
54. Grutzmacher P, Bergmann M, Weinreich T, et al. Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance haemodialysis. Contrib Nephrol 1988;66:104-13.
55. Nowicki M. Erythropoietin and hypertension. J Hum Hypertens 1995;9:81-8.
56. Zehnder C, Zuber M, Sulzer M, et al. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 1992;61:21-5.
57. Carter C, McGee D, Reed D, et al. Hematocrit and the risk of coronary heart disease: the Honolulu Heart Program. Am Heart J 1983;105:674-9.
58. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation 1992;86:803-11.
59. Baer DM, Tekawa IS, Hurley LB. Iron stores are not associated with acute myocardial infarction. Circulation 1994;89:2915-8.
60. Iseki K, Nishime K, Uehara H, et al. Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron 1996;72:30-6.
61. Wakeen M, Zimmerman SW. Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 1998;32:488-93.
62. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
63. Blakeman BP, Sullivan HJ, Foy BK, et al. Internal mammary artery revascularization in the patient on long-term renal dialysis. Ann Thorac Surg 1990;50:776-8.
64. Batiuk TD, Kurtz SB, Oh JK, et al. Coronary artery bypass operation in dialysis patients. Mayo Clin Proc 1991;66:45-53.
65. Yamane H, Fujiwara T, Dokoh S, et al. Coronary artery bypass surgery in dialysis patients. Kyobu Geka Jpn J Thorac Surg 1991;44:937-40.
66. Takeshita S, Yamaguchi T, Isshiki T, et al. Percutaneous transluminal coronary angioplasty and coronary bypass grafting for refractory angina in chronic dialysis patients. J Cardiol 1992;22:383-90.
67. Manske CL, Wang Y, Rector T, et al. Coronary revascularization in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992;340:998-1002.
68. Ko W, Kreiger KH, Isom OW. Cardiopulmonary bypass procedures in dialysis patients. Ann Thorac Surg 1993;55:677-84.
69. Koyanagi T, Nishida H, Kitamura M, et al. Comparison of clinical outcomes of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in renal dialysis patients. Ann Thorac Surg 1996;61:1793-6.
70. Owen CH, Cummings RG, Sell TL, et al. Coronary artery bypass grafting in patients with dialysis-dependent renal failure. Ann Thorac Surg 1994;58:1729-33.
71. Rinehart AL, Herzog CA, Collins AJ, et al. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. Am J Kidney Dis 1995;25:281-90.
72. Garrido P, Bobadilla JF, Albertos J, et al. Cardiac surgery in patients under chronic hemodialysis. Eur J Cardiothorac Surg 1995;9:36-9.
73. Samuels LE, Sharma S, Morris RJ, et al. Coronary artery bypass grafting in patients with chronic renal failure: a reappraisal. J Card Surg 1996;11:128-33.
74. Jahangiri M, Wright J, Edmondson S, et al. Coronary artery bypass graft surgery in dialysis patients. Heart 1997;78:343-5.
75. Chang GL, Ghazzal ZMB, Weintraub WS, et al. Coronary revascu-larization in patients on chronic dialysis. J Am Coll Cardiol 1997;29:180A.
76. Castelli P, Condemi AM, Munari M. Immediate and long-term results of coronary revascularization in patients undergoing chronic hemodialysis. Eur J Cardiothorac Surg 1999;15:51-4.
77. Ahmed WH, Pashos CL, Ayanian JZ, et al. Thirty-day and 1-year mortality in hemodialysis patients undergoing coronary revascularization: results from a national cohort. Circulation 1995;92:1-75.
78. Herzog CA, Ma J, Collins AJ. Dialysis patients in the United States have better long-term outcomes with coronary artery bypass surgery compared to coronary angioplasty. Circulation 1997;96:1-124.
79. Ahmed WH, Shubrooks SJ, Gibson CM, et al. Complications and long-term outcome after percutaneous coronary angioplasty in chronic hemodialysis patients. Am Heart J 1994;128:252-5.
80. Gradaus F, Schoebel FC, Ivens K, et al. High rate of restenosis following coronary angioplasty in patients with chronic renal failure. J Am Coll Cardiol 1997;29:418A.
81. Kahn JK, Rutherford BD, McConahay DR, et al. Short- and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients. Am Heart J 1990;119:484-9.
82. Kober G, Vollbracht C, Giesecke R, et al. Translumine koronare angioplastie bei patienten mit chronischer niereninsuffizienz. Dtsch Med Wochenschr 1986;110:129-34.
83. Reusser LM, Osborn LA, White HJ, et al. Increased morbidity after coronary angioplasty in patients on chronic hemodialysis. Am J Cardiol 1994;73:965-7.
84. Vaitkus PT, Guidera SA. Percutaneous transluminal coronary angioplasty in patients undergoing chronic dialysis. J Intervent Cardiol 1993;6:293-6.
85. Hang CL, Chen MC, Wu BJ, et al. Short- and long-term outcomes after percutaneous transluminal coronary angioplasty in chronic hemodialysis patients. Cathet Cardiovasc Intervent 1999;47:430-3.
86. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary artery bypass surgery, coronary angioplasty, and coronary stenting. Circulation 1998;98:1-78.
87. Marso SP, Gimple LW, Philbrick JT, et al. Failure of percutaneous balloon angioplasty to prevent recurrent coronary events in patients on chronic hemodialysis. Circulation 1996;94:1-571.
88. Dambrin G, Le Feuvre C, Metzger JP, et al. Comparison of coronary stenting in hemodialysis and non hemodialysis patients. J Am Coll Cardiol 1999;33:92A.
89. Opsahl JA, Husebye DG, Helseth HK, et al. Coronary artery bypass surgery in patients on maintenance dialysis: long-term survival. Am J Kidney Dis 1988;12:271-4.